The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Investment is additive to KKR’s existing health care growth strategy
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Subscribe To Our Newsletter & Stay Updated
